NASDAQ:NEO

NeoGenomics (NEO) Stock Forecast, Price & News

$12.42

+0.11 (+0.89%)

(As of 09/27/2023 ET)

Compare

Today's Range: $12.31
▼
$12.63
50-Day Range: $12.15
▼
$17.54
52-Week Range: $6.00
▼
$20.54

Volume: 501,944 shs
Average Volume: 970,827 shs
Market Capitalization: $1.58 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $19.18

NeoGenomics MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.73 Rating Score
Upside/Downside: 54.4% Upside
$19.18 Price Target
Short Interest: Bearish
4.67% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 1.00
Based on 6 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.44) to ($0.31) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.31 out of 5 stars

Medical Sector

415th out of 976 stocks

Testing Laboratories Industry

1st out of 1 stocks

4.4

Analyst's Opinion

Consensus Rating
NeoGenomics has received a consensus rating of Moderate Buy. The company's average rating score is 2.73, and is based on 8 buy ratings, 3 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $19.18, NeoGenomics has a forecasted upside of 54.4% from its current price of $12.42.
Amount of Analyst Coverage
NeoGenomics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

2.0

Short Interest

Percentage of Shares Shorted
4.67% of the outstanding shares of NeoGenomics have been sold short.
Short Interest Ratio / Days to Cover
NeoGenomics has a short interest ratio ("days to cover") of 7.7.
Change versus previous month
Short interest in NeoGenomics has recently increased by 8.96%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
NeoGenomics does not currently pay a dividend.
Dividend Growth
NeoGenomics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for NEO.

2.8

News and Social Media Coverage

News Sentiment
NeoGenomics has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.80 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 6 news articles for NeoGenomics this week, compared to 3 articles on an average week.
Search Interest
Only 3 people have searched for NEO on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.
MarketBeat Follows
Only 3 people have added NeoGenomics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, NeoGenomics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 1.30% of the stock of NeoGenomics is held by insiders.
Percentage Held by Institutions
91.36% of the stock of NeoGenomics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for NeoGenomics are expected to grow in the coming year, from ($0.44) to ($0.31) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of NeoGenomics is -13.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of NeoGenomics is -13.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
NeoGenomics has a P/B Ratio of 1.57. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About NeoGenomics (NASDAQ:NEO) Stock

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates through, Clinical Services and Pharma Services segments. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers. It provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. The company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization, as well as acts as a reference laboratory supplying anatomic pathology testing services. It has a strategic alliance agreement and laboratory services agreement with Inivata Limited. The company was founded in 2001 and is headquartered in Fort Myers, Florida.

NEO Price History

30 days | 90 days | 365 days | Advanced Chart

NEO Stock News Headlines

September 27, 2023 | finance.yahoo.com

Chroma Medicine Strengthens Leadership with the Appointment of Biotech Business Leader Michael A. Kelly to its Board of Directors

September 26, 2023 | thestreet.com

NeoGenomics Deal With GE's Clarient 6 Months Later: Boom or Bust?

September 28, 2023 | Chaikin Analytics (Ad)

Buy This Stock for AI Tidal Wave (not NVDA)

The internet boom made more millionaires than any tech - Microsoft’s CEO says AI has even more potential. Here’s the #1 stock to buy.

September 22, 2023 | msn.com

One year after Hurricane Ian: 10 'truths' about historic storm's impact on Southwest Florida

August 21, 2023 | msn.com

Stephens & Co. Upgrades Neogenomics (NEO)

August 21, 2023 | markets.businessinsider.com

4 Analysts Have This to Say About NeoGenomics

August 11, 2023 | msn.com

Benchmark Maintains Neogenomics (NEO) Buy Recommendation

August 10, 2023 | finance.yahoo.com

NeoGenomics Inc (NG9.BE)

September 28, 2023 | Chaikin Analytics (Ad)

Buy This Stock for AI Tidal Wave (not NVDA)

The internet boom made more millionaires than any tech - Microsoft’s CEO says AI has even more potential. Here’s the #1 stock to buy.

August 9, 2023 | msn.com

Fort Myers-based NeoGenomics grew revenues in Q2, and narrowed its losses

August 9, 2023 | msn.com

NeoGenomics: Asset Growth Yet To Scale Gross Profitability, Reiterate Hold

August 8, 2023 | msn.com

NeoGenomics Raises Annual Guidance After Solid Q2 Earnings Beat

August 8, 2023 | finance.yahoo.com

NeoGenomics (NEO) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

August 8, 2023 | finanznachrichten.de

NeoGenomics, Inc.: NeoGenomics Reports Second Quarter 2023 Results

August 8, 2023 | msn.com

NeoGenomics Non-GAAP EPS of -$0.05 beats by $0.06, revenue of $146.92M beats by $9.49M

August 8, 2023 | finance.yahoo.com

NeoGenomics Reports Second Quarter 2023 Results

August 8, 2023 | seekingalpha.com

NeoGenomics, Inc. 2023 Q2 - Results - Earnings Call Presentation

July 28, 2023 | markets.businessinsider.com

BTIG Reaffirms Their Buy Rating on NeoGenomics (NEO)

July 27, 2023 | markets.businessinsider.com

Craig-Hallum Reaffirms Their Buy Rating on NeoGenomics (NEO)

July 27, 2023 | finanznachrichten.de

NeoGenomics, Inc.: NeoGenomics Announces Medicare Coverage for RaDaR Assay for Minimal Residual Disease and Recurrence in Breast Cancer

July 27, 2023 | finance.yahoo.com

NeoGenomics Announces Medicare Coverage for RaDaR Assay for Minimal Residual Disease and Recurrence in Breast Cancer

July 25, 2023 | finance.yahoo.com

NEO - NeoGenomics, Inc.

July 18, 2023 | finance.yahoo.com

NeoGenomics to Report Second Quarter 2023 Financial Results on August 8, 2023

June 29, 2023 | finanznachrichten.de

NeoGenomics, Inc.: NeoGenomics Expands Board of Directors with Appointments of Three Independent Directors

June 29, 2023 | finance.yahoo.com

NeoGenomics Expands Board of Directors with Appointments of Three Independent Directors

June 22, 2023 | marketwatch.com

Gene Test Service Market 2023 Business Scenario - LabCorp, Quest Diagnostics, Genomic Health, NeoGenomics, Eurofins Scientific

June 15, 2023 | finanznachrichten.de

NeoGenomics, Inc.: NeoGenomics' RaDaR Assay for Minimal Residual Disease Receives First Commercial Coverage

See More Headlines

Receive NEO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NeoGenomics and its competitors with MarketBeat's FREE daily newsletter.

NEO Company Calendar

Last Earnings: 8/08/2023
Today: 9/28/2023
Next Earnings (Estimated): 11/14/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Testing laboratories
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:NEO
CUSIP: N/A
CIK: 1077183
Web: www.neogenomics.com
Phone: (239) 768-0600
Fax: 239-690-4237
Employees: 2,100
Year Founded: 2002

Price Target and Rating

Average Stock Price Forecast: $19.18
High Stock Price Forecast: $25.00
Low Stock Price Forecast: $15.00
Forecasted Upside/Downside: +54.4%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.73
Research Coverage: 11 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.92)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-144,250,000.00
Net Margins: -20.79%
Pretax Margin: -22.75%
Return on Equity: -6.36%
Return on Assets: -3.64%

Debt

Debt-to-Equity Ratio: 0.56
Current Ratio: 6.16
Quick Ratio: 5.90

Sales & Book Value

Annual Sales: $551.62 million
Price / Sales: 2.87
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $7.90 per share
Price / Book: 1.57

Miscellaneous

Outstanding Shares: 127,552,000
Free Float: 125,894,000
Market Cap: $1.58 billion
Optionable: Optionable
Beta: 1.08

Social Links

7 Stocks to Buy And Hold Forever

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

Mr. Christopher Michael Smith BSc (Age 60)
CEO & Director
Comp: $3.52M

Mr. Jeffrey S. Sherman M.B.A. (Age 57)
Chief Financial Officer
Comp: $492.31k

Mr. Vishal Sikri (Age 47)
Pres of Advanced Diagnostics Division
Comp: $1.21M

Mr. Warren Stone (Age 50)
Pres of Clinical Division
Comp: $722.79k

Ms. Cynthia J. Dieter (Age 48)
Chief Accounting Officer

Mr. Greg Sparks
Chief Technology Officer

Ms. Kendra Sweeney
VP of Investor Relations & Communications

Ms. Alicia Olivo (Age 39)
Gen. Counsel & Corp. Sec.

Mr. Hutan Hashemi J.D. (Age 44)
Chief Compliance Officer

Dr. Derek Lyle M.D.
Chief Medical Officer

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

NEO Stock - Frequently Asked Questions

Should I buy or sell NeoGenomics stock right now?: 11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for NeoGenomics in the last twelve months. There are currently 3 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" NEO shares.
View NEO analyst ratings or view top-rated stocks.
What is NeoGenomics' stock price forecast for 2023?: 11 analysts have issued 1-year price targets for NeoGenomics' shares. Their NEO share price forecasts range from $15.00 to $25.00. On average, they predict the company's stock price to reach $19.18 in the next twelve months. This suggests a possible upside of 54.4% from the stock's current price.
View analysts price targets for NEO or view top-rated stocks among Wall Street analysts.
How have NEO shares performed in 2023?: NeoGenomics' stock was trading at $9.24 at the start of the year. Since then, NEO shares have increased by 34.4% and is now trading at $12.42.
View the best growth stocks for 2023 here.
When is NeoGenomics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023.
View our NEO earnings forecast.
How were NeoGenomics' earnings last quarter?: NeoGenomics, Inc. (NASDAQ:NEO) released its earnings results on Tuesday, August, 8th. The medical research company reported ($0.09) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.15) by $0.06. The medical research company had revenue of $146.92 million for the quarter, compared to analysts' expectations of $138.22 million. NeoGenomics had a negative net margin of 20.79% and a negative trailing twelve-month return on equity of 6.36%.
What ETFs hold NeoGenomics' stock?: ETFs with the largest weight of NeoGenomics (NASDAQ:NEO) stock in their portfolio include SPDR S&P Health Care Services ETF (XHS), Invesco S&P SmallCap Health Care ETF (PSCH), WisdomTree BioRevolution Fund (WDNA), First Trust Nasdaq Lux Digital Health Solutions ETF (EKG) and iShares U.S. Healthcare Providers ETF (IHF).SPDR S&P 600 Small Cap ETF (SLY).
What guidance has NeoGenomics issued on next quarter's earnings?: NeoGenomics issued an update on its FY 2023 earnings guidance on Tuesday, August, 8th. The company provided earnings per share guidance of -$0.28--$0.23 for the period, compared to the consensus earnings per share estimate of -$0.36. The company issued revenue guidance of $565.00 million-$575.00 million, compared to the consensus revenue estimate of $562.42 million.
What is Douglas M. VanOort's approval rating as NeoGenomics' CEO?: 116 employees have rated NeoGenomics Chief Executive Officer Douglas M. VanOort on Glassdoor.com. Douglas M. VanOort has an approval rating of 98% among the company's employees. This puts Douglas M. VanOort in the top 20% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of NeoGenomics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other NeoGenomics investors own include Marvell Technology (MRVL), NVIDIA (NVDA), Alibaba Group (BABA), Block (SQ), Inseego (INSG), PayPal (PYPL), Micron Technology (MU), Invitae (NVTA), CRISPR Therapeutics (CRSP) and AbbVie (ABBV).
What is NeoGenomics' stock symbol?: NeoGenomics trades on the NASDAQ under the ticker symbol "NEO."
Who are NeoGenomics' major shareholders?: NeoGenomics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Brown Advisory Inc. (5.17%), State Street Corp (3.86%), Dimensional Fund Advisors LP (2.34%), Geode Capital Management LLC (2.05%), Schroder Investment Management Group (1.56%) and Northern Trust Corp (1.24%). Insiders that own company stock include Bruce K Crowther, Douglas Matthew Brown, George Cardoza, Jennifer Balliet, Kathryn B Mckenzie, Kevin C Johnson, Lawrence Martin Weiss, Mark Mallon, Oort Douglas M Van, Robert J Shovlin, Steven C Jones and William Bonello.
View institutional ownership trends.
How do I buy shares of NeoGenomics?: Shares of NEO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is NeoGenomics' stock price today?: One share of NEO stock can currently be purchased for approximately $12.42.
How much money does NeoGenomics make?: NeoGenomics (NASDAQ:NEO) has a market capitalization of $1.58 billion and generates $551.62 million in revenue each year. The medical research company earns $-144,250,000.00 in net income (profit) each year or ($0.92) on an earnings per share basis.
How many employees does NeoGenomics have?: The company employs 2,100 workers across the globe.
Does NeoGenomics have any subsidiaries?: The following companies are subsidiares of NeoGenomics: Clarient Inc., Clarient Diagnostic Services Inc, Clarient Inc, Cynogen Inc., GE Medical Holding AB., Genesis Acquisition Holding Corp, Genesis Acquisition Holdings Corp., Genoptix, Genoptix Inc., Inivata Inc., Inivata Limited, Inivata Limited., Minuet Diagnostics Inc., NeoGenomics Bioinformatics Inc., NeoGenomics Europe SA, NeoGenomics Foundation Inc, NeoGenomics Laboratories Inc, NeoGenomics Singapore Pte. Ltd, Path Labs LLC, Suzhou NeoGenomics Pharmaceutical Research Co. Limited, Trapelo Health, and Trapelo Health LLC.
Read More
How can I contact NeoGenomics?: NeoGenomics' mailing address is 12701 COMMONWEALTH DRIVE SUITE 9, FORT MYERS FL, 33913. The official website for the company is www.neogenomics.com. The medical research company can be reached via phone at (239) 768-0600, via email at sjones@neogenomics.com, or via fax at 239-690-4237.

This page (NASDAQ:NEO) was last updated on 9/28/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial